Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers

Pharmaceutical Research

Volumn 20, Issue 3, 2003, Pages 390-396

  Usansky, Helen H ^a   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

BBB permeability; BMEC monolayers; Carrier mediated transport; Log BB; Pgp substrates

Indexed keywords

VOLATILE ORGANIC COMPOUND;

ACTIVE TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CALCULATION; CELL ASSAY; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DIFFUSION; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MATHEMATICAL MODEL; MICROVASCULATURE; PERMEABILITY; PREDICTION; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; ENDOTHELIUM, VASCULAR; FORECASTING; LINEAR MODELS; MICE; MICROCIRCULATION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0037337916     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022647903205     Document Type: Article

References (44)

1. M. Feher, E. Sourial, and J. M. Schmidt. A simple model for the prediction of blood-brain partitioning. Int. J. Pharm. 201:239-247 (2000).
2. J. A. Platts, M. H. Abraham, Y. H. Zhao, A. Hersey, L. Ijaz, and D. Butina. Correlation and prediction of a large blood-brain distribution data set - an LFER study. Eur. J. Med. Chem. 36:719-730 (2001).
3. J. M. Luco. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J. Chem. Inf. Comput. Sci. 39:396-404 (1999).
4. H. Murakami, H. Takanaga, H. Matsuo, H. Ohtani, and Y. Sawada. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol. 279:H1022-H1028 (2000).
5. P. Poulin and F. P. Theil. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89:16-35 (2000).
6. M. V. Shah, K. L. Audus, and R. T. Borchardt. The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier. Pharm. Res. 6:624-627 (1989).
7. V. A. Levin. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:682-684 (1980).
8. S. K. Kennedy and D. E. Longnecker. History and principles of anesthesiology. In J. G. Hardman, A. G. Gilman, and L. E. Limbird (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 1996, pp. 682-684.
9. P. Poulin and K. Krishnan. A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals. Hum. Exp. Toxicol. 14:273-280 (1995).
10. A. Leo, C. Hansch, and D. Elkins. Partitioning coefficients and their uses. Chem. Rev. 71:525-616 (1971).
11. M. D. Johnson and B. D. Anderson. In vitro models of the blood-brain barrier to polar permeants: comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells. J. Pharm. Sci. 88:620-625 (1999).
12. K. W. Otis, M. L. Avery, S. M. Broward-Partin, D. K. Hansen, H. W. Behlow, Jr., D. O. Scott, and T. N. Thompson. Evaluation of the BBMEC model for screening the CNS permeability of drugs. J. Pharmacol. Toxicol. Methods 45:71-77 (2001).
13. U. Bickel, T. Yoshikawa, and W. M. Pardridge. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46:247-279 (2001).
14. J. H. Zar. Biostatistical Analysis, Prentice Hall, Englewood Cliffs, New Jersey, 1984.
15. J. Matsuzaki, C. Yamamoto, T. Miyama, H. Takanaga, H. Matsuo, H. Ishizuka, Y. Kawahara, M. Kuwano, M. Naito, T. Tsuruo, and Y. Sawada. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm. Drug Dispos. 20:85-90 (1999).
16. A. J. Dudley, K. Bleasby, and C. D. Brown. The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br. J. Pharmacol. 131:71-79 (2000).
17. U. Mayer, E. Wagenaar, J. H. Beijnen, J. W. Smit, D. K. Meijer, J. van Asperen, P. Borst, and A. H. Schinkel. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. 119:1038-1044 (1996).
18. A. H. Schinkel, J. J. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag, and H. P. te Riele. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502 (1994).
19. SRC PhysProp Database. (http://chemfinder.cambridgesoft.com).
20. S. L. Glynn and M. Yazdanian. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 87:306-310 (1998).
21. D. K. Hansen, D. O. Scott, K. W. Otis, and S. M. Lunte. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J. Pharm. Biomed. Anal. 27:945-958 (2002).
22. P. de Miranda, H. C. Krasny, D. A. Page, and G. B. Elion. The disposition of acyclovir in different species. J. Pharmacol. Exp. Ther. 219:309-315 (1981).
23. R. Cecchelli, B. Dehouck, L. Descamps, L. Fenart, V. Buee-Scherrer, V, C. Duhem, S. Lundquist, M. Rentfel, G. Torpier, and M. P. Dehouck. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36:165-178 (1999).
24. A. Tsuji and I. Tamai. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 36:277-290 (1999).
25. I. Tamai and A. Tsuji. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89:1371-1388 (2000).
26. B. D. Anderson, B. L. Hoesterey, D. C. Baker, and R. E. Galinsky. Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J. Pharmacol. Exp. Ther. 253:113-118 (1990).
27. H. J. Kang, M. G. Wientjes, and J. L. Au. Physiologically based pharmacokinetic models of 2′,3′-dideoxyinosine. Pharm. Res. 14:337-344 (1997).
28. E. V. Batrakova, D. W. Miller, S. Li, V. Y. Alakhov, A. V. Kabanov, and W. F. Elmquist. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296:551-557 (2001).
29. E. V. Batrakova, S. Li, D. W. Miller, and A. V. Kabanov. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16:1366-1372 (1999).
30. C. Rousselle, P. Clair, J. M. Lefauconnier, M. Kaczorek, J. M. Scherrmann, and J. Temsamani. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57:679-686 (2000).
31. 2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines. J. Med. Chem. 40:300-312 (1997).
32. D. S. van I. R. Smolders, L. Nabulsi, K. P. Zuideveld, A. G. de Boer, and D. D. Breimer. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur. J. Pharm. Sci. 14:81-86 (2001).
33. J. H. Lin, M. Chiba, S. K. Balani, I. W. Chen, G. Y. Kwei, K. J. Vastag, and J. A. Nishime. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1111-1120 (1996).
34. M. Yazdanian. Blood-brain barrier properties of human immunodeficiency virus antiretrovirals. J. Pharm. Sci. 88:950-954 (1999).
35. H. Franke, H. Galla, and C. T. Beuckmann. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res. Brain Res. Protoc. 5:248-256 (2000).
36. C. C. Wang, S. Campbell, R. L. Furner, and D. L. Hill. Disposition of all-trans- and 13-cis-retinoic acids and n-hydroxyethyl-retinamide in mice after intravenous administration. Drug Metab. Dispos. 8:8-11 (1980).
37. B. E. Gilbert and P. R. Wyde. Pharmacokinetics of ribavirin aerosol in mice. Antimicrob. Agents Chemother. 32:117-121 (1988).
38. C. B. Washington, H. R. Wiltshire, M. Man, T. Moy, S. R. Harris, E. Worth, P. Weigl, Z. Liang, D. Hall, L. Marriott, and T. F. Blaschke. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab. Dispos. 28:1058-1062 (2000).
39. 14C]urea pharmacokinetics. Am. J. Physiol. 242:R339-R348 (1982).
40. E. Lyubimov, L. B. Lan, I. Pashinsky, and W. D. Stein. Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anticancer Drugs 7:60-69 (1996).
41. J. van Asperen, A. H. Schinkel, J. H. Beijnen, W. J. Nooijen, P. Borst, and O. van Tellingen. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J. Natl. Cancer Inst. 88:994-999 (1996).
42. S. M. El Dareer, V. M. White, F. P. Chen, L. B. Mellet, and D. L. Hill. Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys. Cancer Treat. Rep. 61:1269-1277 (1977).
43. Y. Mitsunaga, H. Takanaga, H. Matsuo, M. Naito, T. Tsuruo, H. Ohtani, and Y. Sawada. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur. J. Pharmacol. 395:193-201 (2000).
44. R. Masereeuw, U. Jaehde, M. W. Langemeijer, A. G. de Boer, and D. D. Breimer. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm. Res. 11:324-330 (1994).